End-Stage Renal Disease in People with Type 2 Diabetes: Systemic Manifestations and Exercise Implications

Physical Therapy

Volumn 84, Issue 5, 2004, Pages 454-463

  Evans, Nancy ^a   Forsyth, Elizabeth ^a  

^a UNIVERSITY OF INDIANAPOLIS   (United States)

Author keywords

Diabetes; Exercise; Nephropathy; Systemic

Indexed keywords

AEROBIC CAPACITY; CLINICAL FEATURE; DIABETIC NEPHROPATHY; DIET RESTRICTION; GLUCOSE UTILIZATION; HUMAN; KINESIOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; TREATMENT INDICATION;

EID: 2342424257     PISSN: 00319023     EISSN: None     Source Type: Journal    
DOI: 10.1093/ptj/84.5.454     Document Type: Review

References (80)

1. Betts EF, Betts JJ, Betts CJ. Pharmacologic management of hyperglycemia in diabetes mellitus: implications for physical therapy. Phys Ther. 1995;75:415-425.
2. Clark CM, Clark PR. Type 2 diabetes and macrovascular disease: epidemiology and etiology. Am Heart J. 1999;138:330-333.
3. Porth CM, Hurwitz LS. Pathophysiology: Concepts of Altered Health States. 4th ed. Philadelphia, Pa: JB Lippincott Co; 1994:928.
4. Zimmerman BR, Walker WA. American Diabetes Association Complete Guide to Diabetes. 2nd ed. Alexandria, Va: American Diabetes Association; 1999.
5. HHS News. US Department of Health and Human Services Web site. Available at: http://www.hhs.gov/news/press/2002pres/20020327.html. Accessed April 2, 2002.
6. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. Diabetes Care. 1998;21:518-524.
7. Bloomgarden ZT. American Diabetes Association annual meeting, 1999: more on cardiovascular disease. Diabetes Care. 2000;23:845-852.
8. Eschwege E, Simon D, Balkau B. The growing burden of diabetes in the world population. Intl Diabet Fed Bul. 1997;42:14-19.
9. Tan GH, Nelson RL. Pharmacologic treatment options for non-insulin-dependent diabetes mellitus. Mayo Clinic Proc. 1996;71:763-768.
10. Goodman CC. The endocrine and metabolic systems. In: Goodman CC, Boissonnault WG, eds. Pathology: Implications for the Physical Therapist. Philadelphia, Pa: WB Saunders Co; 1998:242-258.
11. The Basic Diabetes Information page. American Diabetes Association Web site. Available at: http://www.diabetes.org:80/main/application/commercewf?origin=*. jp&event=link[B]. Accessed September 3, 2001.
12. Ludwig DS, Ebbeling CB. Type 2 diabetes mellitus in children: primary care and pubic health considerations. JAMA. 2001;286: 1427-1430.
13. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med. 1998;158:1855-1867.
14. Jensen T. Pathogenesis of diabetic vascular disease: evidence for the role of reduced heparan sulfate proteoglycan. Diabetes. 1997;46: 98-100.
15. Levin ME, Pfeiffer MA, eds. The Uncomplicated Guide to Diabetes Complications. Alexandria, Va: American Diabetes Association; 1998.
16. Nelson RG, Knowler WC, Pettitt DJ, Bennett PH. Kidney disease in diabetes. In: Harris MI, ed. Diabetes in America. 2nd ed. Bethesda, Md: National Institutes of Health; 1995. NIH publication no. 95-1468.
17. Groggel GC. Diabetic nephropathy. Arch Fam Med. 1996;5:513-521.
18. Foote EF. Prevention and treatment of diabetic nephropathy. Am J Health-System Pharm. 1995;52:1781-1792.
19. Krolewski AS, Warram JH. Natural history of diabetic nephropathy. Diabetes Rev. 1995;3:446-459.
20. Defronzo RA. Diabetic nephropathy: etiologic and therapeutic considerations. Diabetes Rev. 1995;3:510-564.
21. Humphry LL, Ballard DJ, Frohnert PP, et al. Chronic renal failure in non-insulin dependent diabetes mellitus: a population-based study in Rochester, Minnesota. Ann Intern Med. 1989;111:788-796.
22. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis. 1996;27:167-194.
23. Poirier SJ. Preserving the diabetic kidney. J Fam Pract. 1998;46: 21-28.
24. Molitch ME. Management of early diabetic nephropathy. Am J Med. 1997;102:392-398.
25. Hellerstedt WL, Hohnson WJ, Ascher N, et al. Survival rates of 2,728 patients with end stage renal disease. Mayo Clin Proc. 1984;59:776-783.
26. The Kidney Disease of Diabetes page. National Institute of Diabetes & Digestive & Kidney Diseases Web site. Available at: http://www. niddk.nih.gov/health/kidney/pubs/kdd/kdd.htm. Accessed February 26, 2002.
27. Damsgaard EM, Mogensen CE. Microalbuminuria in elderly hyperglycemic patients and controls. Diabetic Med. 1986;3:430-438.
28. Uisitupa M, Siitonen O, Penttila I, et al. Proteinuria in newly diagnosed type II diabetic patients. Diabetes Care. 1987;10:191-194.
29. Chan L, Alfrey AC. Chronic renal failure: manifestations and pathogensis. In: Schrier RW, ed. Renal and Electrolyte Disorders. 5th ed. Philadelphia, Pa: Lippincott-Raven; 1997:507-543.
30. Kraut JA. Uremia. In: Gennari JF, ed. Medical Management of Kidney and Electrolyte Disorders. New York, NY: Marcel Dekker Inc; 2001:39-55.
31. Stribling D, Armstrong FM, Harrison HE. Aldose reductase in the etiology of diabetic complications. J Diabetes Complications. 1989;3: 70-76.
32. Parving HH, Andersen AR, Smidt UM, et al. Diabetic nephropathy and arterial hypertension: the effect of antihypertensive treatment. Diabetes. 1983;32(suppl 2):83-87.
33. Horton R. Trial and technology in nephropathy. Lancet. 1994;344: 1287.
34. Tyler HR. Neurologic disorders in renal failure. Am J Med. 1968;44: 734-748.
35. Gonzalez EA, Martin KJ. Bone and mineral metabolism in chronic renal failure. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. London, United Kingdom: Harcourt Publishers Ltd; 2000: 69.1-69.12.
36. Massry SG. Disorders of divalent ion metabolism. In: Eknoyan G, Knochel JP, eds. Consequences of Renal Failure. Orlando, Fla: Grune & Stratton Inc; 1984:233-263.
37. Patton BM. Neuromuscular complications. In: Eknoyan G, Knochel JP, eds. Consequences of Renal Failure. Orlando, Fla: Grune & Stratton Inc; 1984:281-310.
38. Meema HE, Oreopoulus DG. Morphology, progression, and regression of arterial and periarterial calcification in patients with end-stage renal disease. Radiology. 1986;158:671-677.
39. Winearls CG. Clinical evaluation and manifestations of chronic renal failure. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. London, United Kingdom: Harcourt Publishers Ltd; 2000: 68.1-68.14.
40. Leon AS. Diabetes. In: ACSM's Exercise Management for Persons With Chronic Diseases and Disabilities. Champaign, Ill: Human Kinetics; 1997: 153-183.
41. Bernard GR, Brigham KL. The pulmonary system. In: Eknoyan G, Knochel JP, eds. Consequences of Renal Failure. Orlando, Fla: Grune & Stratton Inc; 1984:113-132.
42. Saxton CR, Smith JW. The immune system and infections. In: Eknoyan G, Knochel JP, eds. Consequences of Renal Failure. Orlando, Fla: Grune & Stratton Inc; 1984:367-403.
43. Sloand JA. Platelet dysfunction and coagulation defects. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. London, United Kingdom: Harcourt Publishers Ltd; 2000:72.1-72.6.
44. Selby JV, FitzSimmons SC, Newman JM, et al. The natural history and epidemiology of diabetic nephropathy. JAMA. 1990;263: 1954-1960.
45. Knochel JP. The biochemistry of renal failure. In: Eknoyan G, Knochel JP, eds. Consequences of Renal Failure. Orlando, Fla: Grune & Stratton Inc; 1984:1-13.
46. Textor SC. Hypertension in patients with renal disease. In: Gennari JF, ed. Medical Management of Kidney and Electrolyte Disorders. New York, NY: Marcel Dekker Inc; 2001:233-263.
47. Tomson CRV. Cardiovascular disease in chronic renal failure. In: Johnson RJ, Feehally J, eds. Comprehensive Clinical Nephrology. London, United Kingdom: Harcourt Publishers Ltd; 2000:70.1-70.14.
48. Blankenship DM, Blachley JD, Gilliam J. Cutaneous manifestations. In: Eknoyan G, Knochel JP, eds. Consequences of Renal Failure. Orlando, Fla: Grune & Stratton Inc; 1984:15-31.
49. Webster SB, Dahlberg PJ. Bullous dermatosis of hemodialysis: case report and review of the dermatological changes in chronic renal failure. Cutis. 1980;25:322-326.
50. Scoggins RB, Arlan WR. Cutaneous manifestations of hyperlipidemia and uremia. Postgrad Med. 1967;42:537-544.
51. Smith AG. Role of the kidney in regulating plasma immunoreactive beta-melanocyte-stimulating hormone. BMJ. 1976;1:874-876.
52. The Complete Book of Men's Health. The male intestinal tract page. Available at: @wysiwyg:1120/http://www.tiscal.co.uk/reference/health/menshealth/part2_014-1. html. Accessed May 5, 2002.
53. Funnell MM, Anderson RM. Working toward the next generation of diabetes self-management education. Am J Prev Med. 2002;22 (suppl 4):3-5.
54. Schneider SH, Ruderman NB. Exercise and NIDDM. Diabetes Care. 1990;13:785-789.
55. Albright A, Franz M, Hornsby G, et al. American College of Sports Medicine position stand: exercise and type 2 diabetes. Med Sci Sports Exerc. 2000;32:1345-1360.
56. Wallberg-Henriksson H, Rincon J, Zierath JR. Exercise in the management of non-insulin-dependent diabetes mellitus. Sports Med. 1998;25:25-35.
57. White RD, Sherman C, Dinubile NA, ed. Exercise in diabetes management. The Physician and Sportsmedicine. 1999;27:63-76.
58. Foreyt JP, Poston WS. The challenge of diet, exercise, and life style modification in the management of the obese diabetic patient. Int J Obes. 1999;23(suppl 7):S5-S11.
59. Gordon NF. The exercise prescription. In: The Health Professional's Guide to Diabetes and Exercise. Alexandria, Va: American Diabetes Association; 1995:71-82.
60. American College of Sports Medicine. Guidelines to Exercise Testing and Exercise Prescription. 5th ed. Philadelphia, Pa: Williams & Wilkins, 1995:206-235.
61. The National Academies Press page. Institute of Medicine Web site. Available at: http://www.nap.edu/books/0309085373/html/. Accessed September 20, 2002.
62. Bouchard CJ, Depres P, Trembleuy A. Exercise and obesity. Obes Res. 1993;1:133-147.
63. Ford ES, Herman WH. Leisure time physical activity patterns in the U.S. diabetic population: findings from the 1990 national health interview survey-health promotion and disease prevention supplement. Diabetes Care. 1995;18:27-33.
64. Vink AL. Neuropathy. In: The Health Professional's Guide to Diabetes and Exercise. Alexandria, Va: American Diabetes Association, 1995: 183-197.
65. Hornsby WG. Resistance training. In: The Health Professional's Guide to Diabetes and Exercise. Alexandria, Va: American Diabetes Association; 1995:85-88.
66. Coyle EF, Hagberg JM, Hurley BS, et al. Carbohydrate feeding during prolonged strenuous exercise can delay fatigue. J Appl Physiol. 1983;55:230-235.
67. Felig WJ, Hagenfeldt PL. Physical exercise and fuel homeostasis in diabetes mellitus. Diabetologia. 1978;14:213-222.
68. White RD, Sherman C, DiNubile NA, eds. Exercise with diabetes. The Physician and Sportsmedicine. 1999;27:77-78.
69. Painter PL. Renal failure. In: ACSM's Exercise Management for Persons With Chronic Diseases and Disabilities. Champaign, Ill: Human Kinetics; 1997:89-91.
70. Painter PL. End-stage renal disease. In: Skinner JS, ed. Exercise Testing and Exercise Prescription for Special Cases. 2nd ed. Media, Pa: Williams & Wilkins; 1993:351-362.
71. Painter PL, Nelson-Worel JN, Gill MM, et al. Effects of exercise training during hemodialysis. Nephron. 1986;43:87-92.
72. Goldberg AP, Geltman EM, Gavien JR, et al. Exercise training reduces coronary risk and effectively rehabilitates hemodialysis patients. Nephron. 1986;42:311-316.
73. Harter HR, Goldberg AP. Endurance exercise training: an effective therapeutic modality for hemodialysis patients. Med Clin North Am. 1985;69:159-174.
74. Carney RM, McKevitt PM, Goldberg AP, et al. Psychological effects of exercise training in hemodialysis patients. Nephron. 1983;33:179.
75. Moore GE, Parsons DB, Stray-Gunderson J, et al. Uremic myopathy limits aerobic capacity in hemodialysis patients. Am J Kidney Dis. 1993;22:277-287.
76. Painter P, Moore G, Carison L, et al. Effects of exercise training plus normalization of hematocrit on exercise capacity and health related quality of life. Am J Kidney Dis. 2002;39:257-265.
77. Goodman CC, Boissonnault WG, Fuller KS. Laboratory tests and values. In: Goodman CC, Boissonnault WG, eds. Pathology: Implications for the Physical Therapist. Philadelphia, Pa: WB Saunders Co; 1998: 838-859.
78. A Guide to Blood Chemistries for Kidney Dialysis Patients page. Colorado HealthSite Web site. Available at: http://www. coloradohealthsite.org/dialysis/bc/bcl.htm?printit. Accessed November 15, 2002.
79. Pagana KD, Pagana TJ. Mosby's Diagnostic and Laboratory Test Reference. 5th ed. St Louis, Mo: Mosby Inc; 2001:676-677.
80. American Diabetes Association. Screening for diabetes. Diabetes Care. 2002;25(suppl 1):S21-S24.